Navigation Links
Halozyme Therapeutics To Present At The BioCentury Newsmakers In The Biotech Industry Conference
Date:9/20/2013

SAN DIEGO, Sept. 20, 2013 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) will be presenting at the BioCentury Newsmakers in the Biotech Industry Conference in New York on Friday, Sept. 27, 2013 at 8:30 a.m. ET/5:30 a.m. PT. Gregory I. Frost, President and Chief Executive Officer, Halozyme Therapeutics, will provide a corporate overview.

(Logo: http://photos.prnewswire.com/prnh/20100302/LA63139LOGO)

The presentation will be webcast through the "Investors" section of Halozyme's corporate website at www.halozyme.com, and a recording will be made available for 90 days following the event. To access the live webcast, please log on to Halozyme's website approximately 15 minutes prior to the presentation to register and download any necessary audio software.

About Halozyme
Halozyme Therapeutics is a biopharmaceutical company dedicated to developing and commercializing innovative products that advance patient care. With a diversified portfolio of enzymes that target the extracellular matrix, the company's research focuses primarily on a family of human enzymes, known as hyaluronidases, which increase the absorption and dispersion of biologics, drugs and fluids. Halozyme's pipeline addresses therapeutic areas, including diabetes, oncology and dermatology that have significant unmet medical need. The company markets Hylenex® recombinant (hyaluronidase human injection) and has partnerships with Roche, Pfizer, Baxter, and Intrexon. Halozyme is headquartered in San Diego, CA. For more information on how we are innovating, please visit our corporate website at www.halozyme.com.<
'/>"/>

SOURCE Halozyme Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Halozyme to Present New Data on PEGPH20 in Pancreatic Cancer at European Cancer Congress
2. Halozyme Announces Roche Receives Marketing Authorization for Herceptin SC in European Union
3. Halozyme Reports Second Quarter 2013 Financial Results
4. Halozyme Provides Update on ViroPharma Phase 2 Trial of Subcutaneous Cinryze (C1 Esterase Inhibitor [Human]) Formulation with rHuPH20
5. Halozyme to Host Second Quarter 2013 Financial Results Conference Call
6. Halozymes Phase 1b Clinical Trial Of PEGPH20 With Gemcitabine Indicates Positive Activity Against Pancreatic Cancer
7. Halozyme Therapeutics Names David A. Ramsay Chief Financial Officer
8. Halozyme Reports First Quarter 2013 Financial Results
9. Halozyme Therapeutics To Present At The Bank Of America Merrill Lynch 2013 Health Care Conference
10. Halozyme Therapeutics Names Matt Posard to Board of Directors
11. Baxter And Halozyme Announce Positive Opinion For HyQvia For Treatment Of Primary And Secondary Immunodeficiencies In The European Union
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... , Aug. 29, 2014 /PRNewswire-iReach/ -- Market ... Scanner Industry, 2009-2019 is a professional and in-depth ... Crystallography Scanner industry . The report firstly reviews ... its classification, application and manufacturing technology. The report ... X-Ray Crystallography Scanner listing their product specification, capacity, ...
(Date:8/29/2014)...  Chuma Holdings, Inc. (OTCBB:CHUM) (the "Company"), an ... services for the lawfully organized cannabis industry, is ... the Company,s name and symbol change request. Effective ... known as Chuma Holdings, Inc. ... with the Company,s wholly-owned subsidiary, Chuma Holdings, Inc., ...
(Date:8/29/2014)... , Aug. 29, 2014 The clinical ... can be the difference between a product,s success or ... map and stratify KOL targets – and then to ... type of strong relationships upon which successful KOL engagement ... pharma companies have identified internal inconsistencies in their KOL ...
Breaking Medicine Technology:X-Ray Crystallography Scanner Industry For Global and Chinese Market Forecast to 2019 2X-Ray Crystallography Scanner Industry For Global and Chinese Market Forecast to 2019 3X-Ray Crystallography Scanner Industry For Global and Chinese Market Forecast to 2019 4X-Ray Crystallography Scanner Industry For Global and Chinese Market Forecast to 2019 5CannaMed Announces Name Change and Trading Symbol Change 2CannaMed Announces Name Change and Trading Symbol Change 3Implementing a Strategic Thought Leader Management & Engagement System 2
... 2011 Nektar Therapeutics (Nasdaq: NKTR ) ... clinical study to evaluate multiple ascending doses of NKTR-181, ... in development as a once- or twice-daily oral tablet ... to address the abuse liability and serious central nervous ...
... 8, 2011 Reportlinker.com announces that a ... its catalogue: Global Intravenous ... http://www.reportlinker.com/p0611078/Global-Intravenous-IV-Solutions-Industry.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Medical_E This report analyzes ... in US$ Million. The report provides separate ...
Cached Medicine Technology:Nektar Initiates Second Phase 1 Clinical Study Evaluating NKTR-181, A Novel Opioid Molecule, for Treatment of Chronic Pain 2Nektar Initiates Second Phase 1 Clinical Study Evaluating NKTR-181, A Novel Opioid Molecule, for Treatment of Chronic Pain 3Nektar Initiates Second Phase 1 Clinical Study Evaluating NKTR-181, A Novel Opioid Molecule, for Treatment of Chronic Pain 4Nektar Initiates Second Phase 1 Clinical Study Evaluating NKTR-181, A Novel Opioid Molecule, for Treatment of Chronic Pain 5Nektar Initiates Second Phase 1 Clinical Study Evaluating NKTR-181, A Novel Opioid Molecule, for Treatment of Chronic Pain 6Global Intravenous (IV) Solutions Industry 2Global Intravenous (IV) Solutions Industry 3Global Intravenous (IV) Solutions Industry 4Global Intravenous (IV) Solutions Industry 5Global Intravenous (IV) Solutions Industry 6Global Intravenous (IV) Solutions Industry 7Global Intravenous (IV) Solutions Industry 8
(Date:8/30/2014)... OR (PRWEB) August 30, 2014 What ... programs? What are the latest trends, concerns, and considerations? ... and Dr. Ken Pendleton recently spoke with Woody Wommack, ... number of current issues in football recruiting. Notably, ... for younger athletes, changes that he thinks are coming ...
(Date:8/30/2014)... Saturday 30 August 2014: The first expert ... novel document compiles current evidence on the diagnosis ... by international experts from three continents. , The ... today on-line in EP Europace (1). ... Rhythm Association (EHRA) of the European Society of ...
(Date:8/30/2014)... Barcelona, Spain Saturday 30 August 2014: The ... oral anticoagulants in pulmonary embolism are published today ... at ESC Congress by Professor Stavros V. Konstantinides ... "2014 ESC Guidelines on the diagnosis and management ... in European Heart Journal (1) and on the ...
(Date:8/30/2014)... 2014: The therapeutic benefit of revascularisation in coronary ... ESC/EACTS revascularisation guidelines presented at ESC Congress by ... of the European Society of Cardiology (ESC) and ... for Cardio-Thoracic Surgery (EACTS). The joint guidelines are ... (1), on the ESC Website (2), in ...
(Date:8/29/2014)... Denver, Colorado (PRWEB) August 29, 2014 The ... indicates that this new program actually is a system that ... relationships. The program was created by Carrie Engel, who actually ... make sure that users will get the best advices out ... renowned romance guru. , This new program is a ...
Breaking Medicine News(10 mins):Health News:Woody Wommack of Rivals.com Discusses the World of NCAA Football Recruiting on SCI TV 2Health News:Woody Wommack of Rivals.com Discusses the World of NCAA Football Recruiting on SCI TV 3Health News:First expert consensus on ventricular arrhythmias published 2Health News:First expert consensus on ventricular arrhythmias published 3Health News:First recommendations on all new oral anticoagulants in pulmonary embolism published 2Health News:ESC/EACTS revascularization guidelines stress benefit of revascularization in stable CAD 2Health News:ESC/EACTS revascularization guidelines stress benefit of revascularization in stable CAD 3Health News:Enchant Him Review Reveals Unique Relationship Tips for Women 2
... is unclear, findings may help improve treatment for psychiatric ... Children with lower IQ have an increased risk of ... problems as adults, a new study that spanned more ... also associated with more persistent depression and anxiety, as ...
... implant makes it more difficult to treat the malignancy, ... Women who have had their breasts augmented with implants ... be treated successfully with a partial-breast radiation treatment known ... , "It,s such a challenge to take care of ...
... The next time you visit a dentist,in the mid-Michigan ... addition to your brushing habits. , ... Health,Care and the Michigan Primary Care Association are spearheading a ... closely on,detecting high blood pressure in patients. , ...
... -- As part of the Dec. 1 observance of ... Pennsylvanians to be tested for HIV - the virus that causes ... the disease and how it is prevented. , ... background, age, ethnicity or race, being tested for HIV is the ...
... offers a low cost, non-invasive alternative to conventional ... having coronary artery disease; true even if the ... a study performed at the Thomas Jefferson University ... patients who had one or more calcified coronary ...
... molecular breast imaging (MBI) can accurately detect small breast ... a study performed at the Mayo Clinic in Rochester, ... lesions smaller than 2 cm in size were imaged ... confirmed in 88 patients," according to Carrie B. Hruska, ...
Cached Medicine News:Health News:Low Childhood IQ Tied to Risk of Later Mental Disorders 2Health News:Radioactive 'Seed' Rx Helps Women With Implants Fight Breast Cancer 2Health News:Radioactive 'Seed' Rx Helps Women With Implants Fight Breast Cancer 3Health News:Dental and Medical Communities Piloting Partnership in Mid-Michigan To Detect and Defeat Disease 2Health News:Dental and Medical Communities Piloting Partnership in Mid-Michigan To Detect and Defeat Disease 3Health News:PA Department of Health Recognizes 20th Anniversary of World AIDS Day; Urges HIV Testing 2
The Emit 2000 Digoxin Calibrators are intended for use with the Emit 2000 Digoxin Assay....
... Akers, our ultimate goal is to provide ... and immediate treatment. Each year millions of ... die from late detection or undetected disease ... cripple nations., ,By developing, manufacturing and marketing ...
... BD Macro-Vue RPR (Rapid Plasma Reagin) ... Tests are nontreponemal testing procedures for ... in A Manual of Tests for ... manual are the most widely used ...
Rapid Plasma Reagin (RPR) set is a non-treponemal flocculation test that is,used for the qualitative and semi-quantitative determination of reagin,antibodies in serum or plasma from persons with syph...
Medicine Products: